Membrane transporters in drug development
Open accessThe DOI matches its Crossref record; 225 of the 225 references it cites were found in a registry or an index.
Abstract
Membrane transporters can be major determinants of the pharmacokinetic, safety and efficacy profiles of drugs. This presents several key questions for drug development, including which transporters are clinically important in drug absorption and disposition, and which in vitro methods are suitable for studying drug interactions with these transporters. In addition, what criteria should trigger follow-up clinical studies, and which clinical studies should be conducted if needed. In this article, we provide the recommendations of the International Transporter Consortium on these issues, and present decision trees that are intended to help guide clinical studies on the currently recognized most important drug transporter interactions. The recommendations are generally intended to support clinical development and filing of a new drug application. Overall, it is advised that the timing of transporter investigations should be driven by efficacy, safety and clinical trial enrolment questions (for example, exclusion and inclusion criteria), as well as a need for further understanding of the absorption, distribution, metabolism and excretion properties of the drug molecule, and information required for drug labelling.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“To date, the human genome has been proven to have more than 400 membrane transporters, which are divided into two families: ATP binding cassette (ABC) and solute carrier (SLC) transporters [114].”
From Drug Resistance in Colorectal Cancer: From Mechanism to Clinic (2022) · cites this paper as [114]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Goodman & Gilman's The Pharmacological Basis of Therapeutics
Brunton, L. L. (1985) · Cited by 7,321
Goodman and Gilman's the Pharmacological Basis of Therapeutics
Stigelman, W. H., & Pharm, D. (1986) · Military Medicine · doi:10.1093/milmed/151.1.386 · Cited by 6,782
Amidon, G. L., Lennernäs, H., Shah, V. P., & Crison, J. R. (1995) · Pharmaceutical Research · doi:10.1023/a:1016212804288 · Cited by 5,430
A multidrug resistance transporter from human MCF-7 breast cancer cells
Doyle, L. A., Yang, W., Abruzzo, L. V., Krogmann, T., Gao, Y., Rishi, A. K., & Ross, D. D. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.26.15665 · Cited by 2,322
Schinkel, A. H., Smit, J. J. M., van Tellingen, O., Beijnen, J. H., Wagenaar, E., van Deemter, L., Mol, C. A. A. M., van der Valk, M. A., Robanus-Maandag, E. C., te Riele, H. P. J., et al. (1994) · Cell · doi:10.1016/0092-8674(94)90212-7 · Cited by 2,281
SLCO1B1 Variants and Statin-Induced Myopathy — A Genomewide Study
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0801936 · Cited by 2,043
Structure of P-Glycoprotein Reveals a Molecular Basis for Poly-Specific Drug Binding
Aller, S. G., Yu, J., Ward, A., Weng, Y., Chittaboina, S., Zhuo, R., Harrell, P. M., Trinh, Y. T., Zhang, Q., Urbatsch, I. L., et al. (2009) · Science · doi:10.1126/science.1168750 · Cited by 1,929
Wu, C.-Y., & Benet, L. Z. (2005) · Pharmaceutical Research · doi:10.1007/s11095-004-9004-4 · Cited by 1,401
Self-citationMammalian drug efflux transporters of the ATP binding cassette (ABC) family: an overview
Schinkel, A. H., & Jonker, J. W. (2003) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(02)00169-2 · Cited by 1,386
Mammalian drug efflux transporters of the ATP binding cassette (ABC) family: an overview
Schinkel, A. H., & Jonker, J. W. (2012) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2012.09.027 · Cited by 1,231
Cited by
Items 301–400 of 1,008
Harwood, M. D., Neuhoff, S., Carlson, G., Warhurst, G., & Rostami‐Hodjegan, A. (2012) · Biopharmaceutics & Drug Disposition · doi:10.1002/bdd.1810 · Cited by 114
Tornio, A., Niemi, M., Neuvonen, P. J., & Backman, J. T. (2012) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2012.03.001 · Cited by 123
Self-citationWatanabe, T., Kusuhara, H., & Sugiyama, Y. (2010) · Journal of Pharmacokinetics and Pharmacodynamics · doi:10.1007/s10928-010-9176-y · Cited by 111
Self-citationCheung, K. W. K., van Groen, B. D., Spaans, E., van Borselen, M. D., de Bruijn, A. C. J. M., Simons-Oosterhuis, Y., Tibboel, D., Samsom, J. N., Verdijk, R. M., Smeets, B., et al. (2019) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.1516 · Cited by 111
Self-citationHendrickx, R., Johansson, J. G., Lohmann, C., Jenvert, R.-M., Blomgren, A., Börjesson, L., & Gustavsson, L. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm400966v · Cited by 109
Ion channels and transporters in the development of drug resistance in cancer cells
Hoffmann, E. K., & Lambert, I. H. (2014) · Philosophical Transactions of the Royal Society B Biological Sciences · doi:10.1098/rstb.2013.0109 · Cited by 116
Challenges in inhaled product development and opportunities for open innovation
Forbes, B., Asgharian, B., Dailey, L. A., Ferguson, D., Gerde, P., Gumbleton, M., Gustavsson, L., Hardy, C. J., Hassall, D. G., Jones, R., et al. (2010) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2010.11.004 · Cited by 120
Higgins, J. W., Bedwell, D. W., & Zamek‐Gliszczynski, M. J. (2012) · Drug Metabolism and Disposition · doi:10.1124/dmd.112.044875 · Cited by 108
Self-citationUlvestad, M., Nordell, P., Asplund, A., Rehnström, M., Jacobsson, S., Holmgren, G., Davidson, L., Brolén, G., Edsbagge, J., Björquist, P., et al. (2013) · Biochemical Pharmacology · doi:10.1016/j.bcp.2013.06.029 · Cited by 116
Ito, S., Kusuhara, H., Kumagai, Y., Moriyama, Y., Inoue, K., Kondo, T., Nakayama, H., Horita, S., Tanabe, K., Yuasa, H., et al. (2012) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2012.138 · Cited by 108
Self-citationIeiri, I., Doi, Y., Maeda, K., Sasaki, T., Kimura, M., Hirota, T., Chiyoda, T., Miyagawa, M., Irie, S., Iwasaki, K., et al. (2011) · The Journal of Clinical Pharmacology · doi:10.1177/0091270011408612 · Cited by 107
Self-citationVaidyanathan, J., Yoshida, K. J., Arya, V., & Zhang, L. (2016) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.723 · Cited by 107
Self-citationStructural basis for polyspecificity in the POT family of proton‐coupled oligopeptide transporters
Lyons, J. A., Parker, J. L., Solcan, N., Brinth, A., Li, D., Shah, S. T., Caffrey, M., & Newstead, S. (2014) · EMBO reports · doi:10.15252/embr.201338403 · Cited by 109
Substrate-Dependent Ligand Inhibition of the Human Organic Cation Transporter OCT2
Belzer, M., Morales, M. N., Jagadish, B., Mash, E. A., & Wright, S. H. (2013) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.113.203257 · Cited by 107
Self-citationVildhede, A., Wiśniewski, J. R., Norén, A., Karlgren, M., & Artursson, P. (2015) · Journal of Proteome Research · doi:10.1021/acs.jproteome.5b00334 · Cited by 105
Elgart, A., Cherniakov, I., Aldouby, Y., Domb, A. J., & Hoffman, A. (2013) · Pharmaceutical Research · doi:10.1007/s11095-013-1063-y · Cited by 111
Ulvestad, M., Skottheim, I. B., Jakobsen, G. S., Bremer, S., Molden, E., Åsberg, A., Hjelmesaeth, J. S., Andersson, T. B., Sandbu, R., & Christensen, H. (2012) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2012.261 · Cited by 118
Feng, B., LaPerle, J. L., Chang, G., & Varma, M. V. (2010) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.2010.482930 · Cited by 105
Oral Absorption, Intestinal Metabolism and Human Oral Bioavailability
El-Kattan, A., & Varm, M. (2012) · Topics on Drug Metabolism · doi:10.5772/31087 · Cited by 102
Kimoto, E., Yoshida, K. J., Balogh, L. M., Bi, Y., Maeda, K., El‐Kattan, A. F., Sugiyama, Y., & Lai, Y. (2012) · Molecular Pharmaceutics · doi:10.1021/mp300379q · Cited by 106
Self-citationHow to design the surface of peptide-loaded nanoparticles for efficient oral bioavailability?
Malhaire, H., Gimel, J.-C., Roger, E., Benoît, J., & Lagarce, F. (2016) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2016.03.011 · Cited by 107
Munnawar, I., Iqbal, S. S., Anwar, M. N., Batool, M., Tariq, S., Faitma, N., Khan, A. L., Khan, A. U., Nazar, U., Jamil, T., et al. (2017) · Carbohydrate Polymers · doi:10.1016/j.carbpol.2017.08.036 · Cited by 105
Glassman, P. M., Villa, C. H., Ukidve, A., Zhao, Z., Smith, P. N., Mitragotri, S., Russell, A. J., Brenner, J. S., & Muzykantov, V. R. (2020) · Pharmaceutics · doi:10.3390/pharmaceutics12050440 · Cited by 113
Varma, M. V. S., Lai, Y., Kimoto, E., Goosen, T. C., El‐Kattan, A. F., & Kumar, V. S. (2013) · Pharmaceutical Research · doi:10.1007/s11095-012-0956-5 · Cited by 105
Deo, A. K., Theil, F.-P., & Nicolas, J.-M. (2013) · Molecular Pharmaceutics · doi:10.1021/mp300570z · Cited by 104
Edoxaban drug–drug interactions with ketoconazole, erythromycin, and cyclosporine
Parasrampuria, D. A., Mendell, J., Shi, M., Matsushima, N., Zahir, H., & Truitt, K. (2016) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.13092 · Cited by 104
Reichel, A., & Lienau, P. (2015) · Handbook of experimental pharmacology · doi:10.1007/164_2015_26 · Cited by 116
Edoxaban Transport via P-Glycoprotein Is a Key Factor for the Drug’s Disposition
Mikkaichi, T., Yoshigae, Y., Masumoto, H., Imaoka, T., Rozehnal, V., Fischer, T., Okudaira, N., & Izumi, T. (2014) · Drug Metabolism and Disposition · doi:10.1124/dmd.113.054866 · Cited by 104
Bowman, C. M., & Benet, L. Z. (2018) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2018.08.008 · Cited by 111
Self-citationHan, T. K., Everett, R., Proctor, W. R., Ng, C. M., Costales, C., Brouwer, K. L. R., & Thakker, D. R. (2013) · Molecular Pharmacology · doi:10.1124/mol.112.084517 · Cited by 103
Self-citationThe Past, Present and Future of Intestinal In Vitro Cell Systems for Drug Absorption Studies
Youhanna, S. C., & Lauschke, V. M. (2020) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2020.07.001 · Cited by 115
Physiologically based pharmacokinetic (PBPK) modelling tools: how to fit with our needs?
Bouzom, F., Ball, K., Perdaems, N., & Walther, B. (2012) · Biopharmaceutics & Drug Disposition · doi:10.1002/bdd.1767 · Cited by 99
A ‘rule of 0.5’ for the metabolite-likeness of approved pharmaceutical drugs
O’Hagan, S., Swainston, N., Handl, J., & Kell, D. B. (2014) · Metabolomics · doi:10.1007/s11306-014-0733-z · Cited by 109
Russell, S. E., Rachlin, A. B., Smith, K. L., Muschamp, J., Berry, L., Zhao, Z., & Chartoff, E. H. (2014) · Biological Psychiatry · doi:10.1016/j.biopsych.2013.07.042 · Cited by 102
Chu, X., Bleasby, K., Chan, G. H., Nunes, I., & Evers, R. (2016) · Drug Metabolism and Disposition · doi:10.1124/dmd.115.067694 · Cited by 107
Self-citationCheng, B., Ren, Y., Niu, X., Wang, W., Wang, S., Tu, Y., Liu, S., Wang, J., Yang, D., Liao, G., et al. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c00574 · Cited by 102
Gronich, N., Stein, N., & Muszkat, M. (2021) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.2369 · Cited by 112
Elsby, R., Martin, P. D., Surry, D. D., Sharma, P. K., & Fenner, K. S. (2015) · Drug Metabolism and Disposition · doi:10.1124/dmd.115.066795 · Cited by 104
Xia, F., Hou, W., Zhang, C., Zhi, X., Cheng, J. Q., de la Fuente, J. M., Song, J., & Cui, D. (2017) · Acta Biomaterialia · doi:10.1016/j.actbio.2017.12.034 · Cited by 101
Onozato, D., Yamashita, M., Nakanishi, A., Akagawa, T., Kida, Y., Ogawa, I., Hashita, T., Iwao, T., & Matsunaga, T. (2018) · Drug Metabolism and Disposition · doi:10.1124/dmd.118.080374 · Cited by 102
Yin, Q., Shen, J., Chen, L., Zhang, Z., Gu, W., & Li, Y. (2012) · Biomaterials · doi:10.1016/j.biomaterials.2012.05.039 · Cited by 100
Application of PBPK modelling in drug discovery and development at Pfizer
Jones, H. M., Dickins, M., Youdim, K., Gosset, J. R., Attkins, N. J., Hay, T. L., Gurrell, I. K., Logan, Y. R., Bungay, P. J., Jones, B. C., et al. (2012) · Xenobiotica · doi:10.3109/00498254.2011.627477 · Cited by 92
Apical ABC Transporters and Cancer Chemotherapeutic Drug Disposition
Durmuş, S., Hendrikx, J. J. M. A., & Schinkel, A. H. (2015) · Advances in cancer research · doi:10.1016/bs.acr.2014.10.001 · Cited by 108
Hu, T., To, K. K. W., Wang, L., Zhang, L., Lu, L., Shen, J., Chan, R. L. Y., Li, M., Yeung, J. H. K., & Cho, C. H. (2014) · Phytomedicine · doi:10.1016/j.phymed.2014.06.013 · Cited by 99
Self-citationShirasaka, Y., Shichiri, M., Mori, T., Nakanishi, T., & Tamai, I. (2013) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.23653 · Cited by 99
Lenvatinib in hepatocellular carcinoma: Resistance mechanisms and strategies for improved efficacy
Qin, Y., Han, S., Yu, Y., Ding, Q., Ran, M., Yang, M., Liu, Y., Li, Y., Lu, L., Liu, Y., et al. (2024) · Liver International · doi:10.1111/liv.15953 · Cited by 112
Izumi, S., Nozaki, Y., Komori, T., Maeda, K., Takenaka, O., Kusano, K., Yoshimura, T., Kusuhara, H., & Sugiyama, Y. (2013) · Drug Metabolism and Disposition · doi:10.1124/dmd.113.052290 · Cited by 99
Self-citationMüller, F., Pontones, C. A., Renner, B., Mieth, M., Hoier, E., Auge, D., Maas, R., Zolk, O., & Fromm, M. F. (2014) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-014-1770-2 · Cited by 101
Prediction of Pharmacokinetics and Drug–Drug Interactions When Hepatic Transporters are Involved
Li, R., Barton, H. A., & Varma, M. V. S. (2014) · Clinical Pharmacokinetics · doi:10.1007/s40262-014-0156-z · Cited by 103
Ménochet, K., Kenworthy, K. E., Houston, J. B., & Galetin, A. (2011) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.111.187112 · Cited by 105
Sedykh, A., Fourches, D., Duan, J., Hucke, O., Garneau, M., Zhu, H., Bonneau, P., & Tropsha, A. (2013) · Pharmaceutical Research · doi:10.1007/s11095-012-0935-x · Cited by 94
Metabolomic and Genome‐wide Association Studies Reveal Potential Endogenous Biomarkers for OATP1B1
Yee, S. W., Giacomini, M., Hsueh, C., Weitz, D., Liang, X., Goswami, S., Kinchen, J. M., Coelho, A., Zur, A. A., Mertsch, K., et al. (2016) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.434 · Cited by 99
Self-citationInvestigational drugs for hyperuricemia, an update on recent developments
Pascart, T., & Richette, P. (2018) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2018.1471133 · Cited by 99
Bierbaumer, L., Schwarze, U. Y., Gruber, R., & Neuhaus, W. (2018) · Tissue Barriers · doi:10.1080/21688370.2018.1479568 · Cited by 105
Skin metabolism phase I and phase II enzymes in native and reconstructed human skin: a short review
Kazem, S., Linssen, E. C., & Gibbs, S. (2019) · Drug Discovery Today · doi:10.1016/j.drudis.2019.06.002 · Cited by 104
Бажанова, Е. Д., Kozlov, А. А., & Litovchenko, A. V. (2021) · Brain Sciences · doi:10.3390/brainsci11050663 · Cited by 106
Magdy, T., Jouni, M., Kuo, H., Weddle, C. J., Lyra‐Leite, D. M., Fonoudi, H., Romero‐Tejeda, M., Gharib, M., Javed, H., Fajardo, G., et al. (2021) · Circulation · doi:10.1161/circulationaha.121.055801 · Cited by 104
Higgins, J. W., Bao, J., Ke, A. B., Manro, J. R., Fallon, J. K., Smith, P. C., & Zamek‐Gliszczynski, M. J. (2013) · Drug Metabolism and Disposition · doi:10.1124/dmd.113.054783 · Cited by 101
Self-citationDi, L., Feng, B., Goosen, T. C., Lai, Y., Steyn, S. J., Varma, M. V. S., & Obach, R. S. (2013) · Drug Metabolism and Disposition · doi:10.1124/dmd.113.054031 · Cited by 107
Jiang, W., & Hu, M. (2012) · RSC Advances · doi:10.1039/c2ra01369j · Cited by 106
Cronin-Fenton, D. P., Damkier, P., & Lash, T. L. (2013) · Future Oncology · doi:10.2217/fon.13.168 · Cited by 102
Rankovic, Z. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b01469 · Cited by 91
RetractedEffinger, A., O’Driscoll, C. M., McAllister, M. S., & Fotaki, N. (2018) · Journal of Pharmacy and Pharmacology · doi:10.1111/jphp.12928 · Cited by 101
Organic Anion Transporting Polypeptides: Emerging Roles in Cancer Pharmacology
Schulte, R. R., & Ho, R. H. (2019) · Molecular Pharmacology · doi:10.1124/mol.118.114314 · Cited by 89
Role of organic cation transporters in drug–drug interaction
Koepsell, H. (2015) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.2015.1069274 · Cited by 100
Suenderhauf, C., & Parrott, N. J. (2012) · Pharmaceutical Research · doi:10.1007/s11095-012-0911-5 · Cited by 107
Influence of Polymorphic OATP1B-Type Carriers on the Disposition of Docetaxel
de Graan, A. M., Lancaster, C. S., Obaidat, A., Hagenbuch, B., Elens, L., Friberg, L. E., de Bruijn, P., Hu, S., Gibson, A. A., Bruun, G. H., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-0761 · Cited by 95
Cell Volume Regulation in Epithelial Physiology and Cancer
Pedersen, S. F., Hoffmann, E. K., & Novak, I. (2013) · Frontiers in Physiology · doi:10.3389/fphys.2013.00233 · Cited by 94
“Many factors are involved in resistance of cancer cells, such as decreased drug uptake, increased drug efflux, detoxification, increased DNA repair, and dys-regulation of apoptotic signaling (Krishna and Mayer, 2000; Stavrovskaya, 2000; Lothstein et al., 2001; Giacomini et al., 2010).”
Legge, S. E., Hamshere, M. L., Ripke, S., Pardiñas, A. F., Goldstein, J. I., Rees, E., Richards, A. L., Leonenko, G., Jorskog, L. F., Chambert, K. D., et al. (2016) · Molecular Psychiatry · doi:10.1038/mp.2016.97 · Cited by 100
Sandoval, P. J., Zorn, K. M., Clark, A. M., Ekins, S., & Wright, S. H. (2018) · Molecular Pharmacology · doi:10.1124/mol.117.111443 · Cited by 94
Self-citationThe pharmacogenetics of natural products: A pharmacokinetic and pharmacodynamic perspective
Rao, T., Tan, Z., Peng, J., Guo, Y., Chen, Y., Zhou, H., & Ouyang, D. (2019) · Pharmacological Research · doi:10.1016/j.phrs.2019.104283 · Cited by 102
Drug-loaded gold plasmonic nanoparticles for treatment of multidrug resistance in cancer
Lee, S., Kim, H. J., Kim, S. Y., Kwon, M. K., Kim, S., Cho, A. E.-H., Yun, M., Shin, J., & Yoo, K. (2013) · Biomaterials · doi:10.1016/j.biomaterials.2013.11.068 · Cited by 97
Zamek‐Gliszczynski, M. J., Bedwell, D. W., Bao, J., & Higgins, J. W. (2012) · Drug Metabolism and Disposition · doi:10.1124/dmd.112.046508 · Cited by 103
Self-citationHira, D., & Terada, T. (2017) · Biochemical Pharmacology · doi:10.1016/j.bcp.2017.10.004 · Cited by 95
Lee, S. H., Kim, H. Y., Back, S. Y., & Han, H. (2017) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2018.1418854 · Cited by 100
O’Hagan, S., Muelas, M. W., Day, P. J., Lundberg, E. K., & Kell, D. B. (2018) · Cell Systems · doi:10.1016/j.cels.2018.01.003 · Cited by 103
Lipidic prodrug approach for improved oral drug delivery and therapy
Marković, M., Ben‐Shabat, S., Keinan, S., Aponick, A., Zimmermann, E. M., & Dahan, A. (2018) · Medicinal Research Reviews · doi:10.1002/med.21533 · Cited by 97
Zhang, C., Zuo, Z., Kwan, P., & Baum, L. (2011) · Epilepsia · doi:10.1111/j.1528-1167.2011.03140.x · Cited by 98
Wagner, D. J., Hu, T., & Wang, J. (2016) · Pharmacological Research · doi:10.1016/j.phrs.2016.06.002 · Cited by 101
Impact of Membrane Drug Transporters on Resistance to Small-Molecule Tyrosine Kinase Inhibitors
Neul, C., Schaeffeler, E., Sparreboom, A., Laufer, S., Schwab, M. G., & Nies, A. T. (2016) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2016.08.003 · Cited by 101
Metallic nano/microglasses: new approaches in nanostructured materials science
Andrievski, R. A. (2013) · Physics-Uspekhi · doi:10.3367/ufne.0183.201303c.0277 · Cited by 92
Schluep, T., Lickliter, J., Hamilton, J., Lewis, D. L., Lai, C., Lau, J. Y., Locarnini, S. A., Gish, R. G., & Given, B. D. (2017) · Clinical Pharmacology in Drug Development · doi:10.1002/cpdd.318 · Cited by 90
Predicting drug-induced liver injury: The importance of data curation
Kotsampasakou, E., Montanari, F., & Ecker, G. F. (2017) · Toxicology · doi:10.1016/j.tox.2017.06.003 · Cited by 93
Orange and apple juice greatly reduce the plasma concentrations of the OATP2B1 substrate aliskiren
Tapaninen, T., Neuvonen, P. J., & Niemi, M. (2010) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2010.03898.x · Cited by 92
Self-citationCaco-2 Cell Conditions Enabling Studies of Drug Absorption from Digestible Lipid-Based Formulations
Keemink, J., & Bergström, C. A. S. (2018) · Pharmaceutical Research · doi:10.1007/s11095-017-2327-8 · Cited by 87
NLA Task Force on Statin Safety - 2014 update
Jacobson, T. A. (2014) · Journal of clinical lipidology · doi:10.1016/j.jacl.2014.03.003 · Cited by 96
Badée, J., Achour, B., Rostami‐Hodjegan, A., & Galetin, A. (2015) · Drug Metabolism and Disposition · doi:10.1124/dmd.114.062034 · Cited by 91
Biomarkers for In Vivo Assessment of Transporter Function
Müller, F., Sharma, A., König, J., & Fromm, M. F. (2018) · Pharmacological Reviews · doi:10.1124/pr.116.013326 · Cited by 92
A Comprehensive Review of Drug–Drug Interactions with Metformin
Stage, T. B., Brøsen, K., & Christensen, M. M. H. (2015) · Clinical Pharmacokinetics · doi:10.1007/s40262-015-0270-6 · Cited by 97
Feier, D. S., Balássy, C., Bastati, N., Stift, J., Badea, R. I., & Ba‐Ssalamah, A. (2013) · Radiology · doi:10.1148/radiol.13122482 · Cited by 90
Li, Y., Lin, J., Cai, Z., Wang, P., Luo, Q., Yao, C., Zhang, Y., Hou, Z., Liu, J., & Liu, X. (2020) · Journal of Controlled Release · doi:10.1016/j.jconrel.2020.02.025 · Cited by 92
Deo, A. K., Prasad, B., Balogh, L. M., Lai, Y., & Unadkat, J. D. (2012) · Drug Metabolism and Disposition · doi:10.1124/dmd.111.043810 · Cited by 90
Long-acting κ opioid antagonists nor-BNI, GNTI and JDTic: pharmacokinetics in mice and lipophilicity
Munro, T. A., Berry, L. M., Van’t Veer, A., Béguin, C., Carroll, F. I., Zhao, Z., Carlezon, W. A., & Cohen, B. M. (2012) · BMC Pharmacology · doi:10.1186/1471-2210-12-5 · Cited by 87
Paxton, J. W. (2012) · InTech eBooks · doi:10.5772/1180 · Cited by 96
Highlighting membrane protein structure and function: A celebration of the Protein Data Bank
Li, F., Egea, P. F., Vecchio, A. J., Asial, I., Gupta, M., Paulino, J., Bajaj, R., Dickinson, M. S., Ferguson-Miller, S., Monk, B. C., et al. (2021) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2021.100557 · Cited by 81
Pharmacogenomics for the efficacy and side effects of antihistamines
Li, L., Liu, R., Peng, C., Chen, X., & Li, J. (2022) · Experimental Dermatology · doi:10.1111/exd.14602 · Cited by 101
DrugMAP: molecular atlas and pharma-information of all drugs
Li, F., Yin, J., Lu, M., Mou, M., Li, Z., Zeng, Z., Tan, Y. C., Wang, S., Chu, X., Dai, H., et al. (2022) · Nucleic Acids Research · doi:10.1093/nar/gkac813 · Cited by 93
Self-citationVizirianakis, I. S. (2010) · Nanomedicine Nanotechnology Biology and Medicine · doi:10.1016/j.nano.2010.11.002 · Cited by 93
Pochini, L., Galluccio, M., Scalise, M., Console, L., & Indiveri, C. (2018) · SLAS DISCOVERY · doi:10.1177/2472555218812821 · Cited by 91
VARIDT 2.0: structural variability of drug transporter
Fu, T., Li, F., Zhang, Y., Yin, J., Qiu, W., Li, X., Liu, X., Xin, W., Wang, C., Yu, L., et al. (2021) · Nucleic Acids Research · doi:10.1093/nar/gkab1013 · Cited by 90
Metadata
- Authors
- The International Transporter Consortium, Giacomini, K. M., Huang, S.-M., Tweedie, D. J., Benet, L. Z., Brouwer, K. L. R., Chu, X., Dahlin, A., Evers, R., Fischer, V., Hillgren, K. M., Hoffmaster, K. A., Ishikawa, T., Keppler, D., Kim, R. B., Lee, C. A., Niemi, M., Polli, J. W., Sugiyama, Y., Swaan, P. W., Ware, J. A., Wright, S. H., Wah Yee, S., Zamek-Gliszczynski, M. J., & Zhang, L.
- Affiliations
- University of California, San Francisco (US)
- United States Food and Drug Administration (US)
- Boehringer Ingelheim (United States) (US)
- Merck & Co., Inc., Rahway, NJ, USA (United States) (US)
- Abbott (United States) (US)
- Eli Lilly (United States) (US)
- Novartis (United States) (US)
- RIKEN (JP)
- German Cancer Research Center (DE)
- Western University (CA)
- GlaxoSmithKline (United Kingdom) (GB)
- Genentech (US)
- University of Maryland, Baltimore (US)
- University of Arizona (US)
- ORCID
- Venue
- Nature Reviews Drug Discovery
- Published
- 2010-03
- Volume
- 9
- Issue
- 3
- Pages
- 215-236
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- PMC
- PMC3326076
- OpenAlex
- W2079197876
- Cited by
- 3,340
- References
- 225
- Citations by year
- 2026: 105 · 2025: 118 · 2024: 153 · 2023: 175 · 2022: 180 · 2021: 237 · 2020: 187 · 2019: 219 · 2018: 234 · 2017: 216 · 2016: 242 · 2015: 233 · 2014: 248 · 2013: 316 · 2012: 254
- FWCI
- 27.48
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Nature Reviews Drug Discovery (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Scholarship@Western (Western University) (submittedVersion)
- Funders
- National Institutes of Health (GM61390)
- U.S. Food and Drug Administration
- National Institute of General Medical Sciences (GM61390, R01GM041935, U19GM061390, U01GM061390)
- National Institute of Diabetes and Digestive and Kidney Diseases (R01DK080801, R01DK061425)
- National Institute of Environmental Health Sciences (P30ES006694)
- Topics
- Health Sciences › Medicine › Oncology › Drug Transport and Resistance Mechanisms
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Pharmacogenetics and Drug Metabolism
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmaceutical Science › Drug Solubulity and Delivery Systems
- Keywords
- membrane transporters, drug transporters, drug-drug interactions, pharmacokinetics, drug absorption, drug disposition, drug development, drug safety and efficacy, drug labeling
- MeSH terms
- Animals, Computer Simulation, Decision Trees, Drug Interactions, Drug Evaluation, Preclinical, Humans, Drug Approval, Mice, Knockout, Membrane Transport Proteins, Mice, Prescription Drugs, Drug Discovery
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.